 MINNEAPOLIS--BUSINESS WIRE--DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference being held in New Orleans, LA and Virtually from February 9 11, 2022. For information about the event, visit: 